Thyroid Cancer News and Research RSS Feed - Thyroid Cancer News and Research

Thyroid Cancer is cancer that forms in the thyroid gland (an organ at the base of the throat that makes hormones that help control heart rate, blood pressure, body temperature, and weight). Four main types of thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer. The four types are based on how the cancer cells look under a microscope.
Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009. [More]
Study explores outcomes of thyroid surgery in professional singers

Study explores outcomes of thyroid surgery in professional singers

A diagnosis of thyroid cancer can be devastating to professional singers, because surgical removal of the thyroid commonly causes voice changes. Massachusetts Eye and Ear surgeons developed a neural monitoring system to be used intraoperatively to improve outcomes. [More]
Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

PDI, Inc. subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR, the first and only microRNA expression classifier, and ThyGenX Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. [More]
Trained scent dog identifies thyroid cancer in patients’ urine samples

Trained scent dog identifies thyroid cancer in patients’ urine samples

A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Majority of asymptomatic, benign thyroid nodules remain benign during follow-up

Majority of asymptomatic, benign thyroid nodules remain benign during follow-up

After five years of follow-up, a majority of asymptomatic, benign thyroid nodules exhibited no significant change in size, or actually decreased in size, and diagnoses of thyroid cancer were rare, according to a study in the March 3 issue of JAMA. [More]
Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Cancer researchers at Mayo Clinic's campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC) — a lethal tumor with no effective therapies. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Lenvatinib trial offers hope for thyroid cancer patients

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131. [More]
Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. [More]
ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

The American Thyroid Association has championed the effort to include a daily serving of iodine in multivitamin/mineral supplements intended for pregnant and breastfeeding women, and it applauds the new guidelines released by the U.S. Council for Responsible Nutrition advising manufacturers to include 150 micrograms of iodine to these daily supplements. [More]
Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

There are two types of thyroid cells and therefore there are two broad types of thyroid cancer. Medullary carcinoma is derived from parafollicular or C cells, whereas follicular cells give rise to several types of thyroid cancers. [More]
ANSTO launches nuclear medicine program to improve diagnosis, treatment of cancer and heart disease

ANSTO launches nuclear medicine program to improve diagnosis, treatment of cancer and heart disease

You can’t see it, hear it or smell it, and it’s constantly changing: but despite that, Australia’s nuclear scientists have figured out how to more accurately measure the unit of activity for radionuclides, the Becquerel (Bq). [More]
New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data has found a fivefold increase in rates of thyroid during the past 30 years in Queensland, with nearly 500 Queenslanders diagnosed in 2012 compared to less than 50 diagnoses in 1982. [More]
New approach to fighting breast, thyroid cancers

New approach to fighting breast, thyroid cancers

A team of researchers from the University of Alberta has discovered a new approach to fighting breast and thyroid cancers by targeting an enzyme they say is the culprit for the "vicious cycle" of tumour growth, spread and resistance to treatment. [More]
Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. [More]
Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
New research findings on Graves' disease to be highlighted at ATA meeting

New research findings on Graves' disease to be highlighted at ATA meeting

A unique mouse model of Graves' disease, an autoimmune disorder that causes hyperthyroidism, and new research findings that may help improve the treatment of Graves' disease will be highlighted in oral and poster presentations at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
Advertisement